Epilepsy – Early-Life Seizures and Development of Gabaergic Inhibition in The Human Brain

 

Currently used treatments for neonatal seizures that target neuronal GABAA receptors are often ineffective and, based on data from animal models, may actually be detrimental. The goal of this project, led by Drs. Ojemann, Saneto, and Novotny,  is to characterize the development of human cortical GABAergic inhibition from late gestation through early childhood, and further to assess how this development is disrupted by conditions causing seizures in this age group. Results from this study may encourage the reconsideration of the use of GABAergic medications in the treatment of seizures or sedation in infants and neonates, and also suggest better therapeutic alternatives.